ELATIVE

Serial Number 79312182
Registration 6681657
700

Registration Progress

Application Filed
Jan 20, 2021
Under Examination
Approved for Publication
Jan 11, 2022
Published for Opposition
Jan 11, 2022
Registered
Mar 29, 2022

Trademark Image

ELATIVE

Basic Information

Serial Number
79312182
Registration Number
6681657
Filing Date
January 20, 2021
Registration Date
March 29, 2022
Published for Opposition
January 11, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Mar 29, 2022
Registration
Registered
Classes
005 042

Rights Holder

GENFIT

33
Address
885 avenue Eugène Avinée, Parc Eurasanté
F-59120 LOOS
FR

Ownership History

GENFIT

Original Applicant
33
FR

GENFIT

Owner at Publication
33
FR

GENFIT

Original Registrant
33
FR

Legal Representation

Attorney
Brooks R. Bruneau

USPTO Deadlines

Next Deadline
873 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-03-29)
Due Date
March 29, 2028
Grace Period Ends
September 29, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

29 events
Date Code Type Description Documents
Jun 19, 2025 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Sep 12, 2022 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Aug 23, 2022 FIMP P FINAL DISPOSITION PROCESSED Loading...
Aug 23, 2022 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Jun 29, 2022 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
May 8, 2022 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Mar 29, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jan 11, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 11, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 10, 2022 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Dec 22, 2021 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Dec 22, 2021 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Dec 22, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 9, 2021 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Dec 9, 2021 ALIE A ASSIGNED TO LIE Loading...
Dec 8, 2021 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 6, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 6, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 6, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 11, 2021 RFNT P REFUSAL PROCESSED BY IB Loading...
Aug 25, 2021 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Aug 25, 2021 RFRR P REFUSAL PROCESSED BY MPU Loading...
Aug 7, 2021 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Aug 6, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 3, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 12, 2021 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Jun 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 7, 2021 LIMI I LIMITATION FROM ORIGINAL APPLICATION ENTERED Loading...
Jun 3, 2021 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; organic preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; diagnostic preparations for medical use; diagnostic reagents for medical use
Class 042
Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for pharmaceutical products for others, in particular conducting clinical trials for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely, providing information, results and data relating to scientific or medical research and development of pharmaceutical products, via an online searchable database; conducting clinical trials for others; pharmaceutical and biological product development and research services for third parties; conducting clinical research for others; evaluation of the efficacy of pharmaceutical products; clinical product development services

Classification

International Classes
005 042